Key clinical point: Drugs commonly used to treat multiple myeloma carry cardiovascular risks that should be carefully monitored.
Major finding: Cardiovascular adverse events occurred in 33 of the 65 patients (51%) randomized to carfilzomib, compared with 5 of 30 patients (17%) assigned to bortezomib.
Study details: The ongoing PROTECT trial enrolled 95 patients with relapsed multiple myeloma and randomized them to receive carfilzomib or bortezomib.
Disclosures: The PROTECT study is sponsored by Millennium Pharmaceuticals. Dr. Cornell reported having no financial disclosures.
REPORTING FROM ACC CARDIO-ONCOLOGY
This Week's Must Reads
Must Reads in Lymphoma & Plasma Cell Disorders
Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology
Haplo-HCT shows viability in DLBCL, Dreger P et al. Blood Adv. 2019 Feb 12;3(3):360-9